52 studies found for:    "Acinic cell carcinoma"
Show Display Options
Rank Status Study
21 Recruiting CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Other: laboratory biomarker analysis
22 Active, not recruiting Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: falimarev;   Biological: inalimarev;   Biological: sargramostim;   Other: laboratory biomarker analysis
23 Recruiting Combination Chemotherapy With or Without Oregovomab Followed By Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Biological: oregovomab;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Drug: fluorouracil
24 Recruiting Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of Unknown Primary;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Duct Cell Adenocarcinoma of the Pancreas;   Intestinal Adenocarcinoma of the Stomach;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Carcinoma of Unknown Primary;   Metastatic Extrahepatic Bile Duct Cancer;   Mixed Adenocarcinoma of the Stomach;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Newly Diagnosed Carcinoma of Unknown Primary;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Gallbladder Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Gallbladder Cancer;   Stage IVB Rectal Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
25 Completed
Has Results
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IV Pancreatic Cancer
Interventions: Drug: bortezomib;   Drug: carboplatin;   Other: laboratory biomarker analysis
26 Completed Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: sunitinib malate
27 Active, not recruiting Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: dasatinib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Other: immunohistochemistry staining method
28 Recruiting Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer
Interventions: Drug: porfimer sodium;   Procedure: endoscopic ultrasonography;   Procedure: photodynamic therapy;   Drug: gemcitabine hydrochloride
29 Recruiting Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: 5-fluorouracil;   Drug: capecitabine;   Radiation: radiation;   Procedure: surgery;   Drug: gemcitabine  hydrochloride
30 Active, not recruiting Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib;   Drug: sirolimus;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18
31 Recruiting Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alisertib;   Drug: gemcitabine
32 Recruiting Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Radiation: hyperfractionated radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiosurgery;   Procedure: diffusion-weighted magnetic resonance imaging
33 Completed Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Conditions: High-grade Salivary Gland Carcinoma;   High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
34 Active, not recruiting Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Anaplastic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor;   Salivary Gland Poorly Differentiated Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
35 Terminated Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Occult Non-small Cell Lung Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Anaplastic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor;   Salivary Gland Poorly Differentiated Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Lung Dysplasia;   Stage 0 Esophageal Cancer;   Stage 0 Non-small Cell Lung Cancer;   Stage I Adenoid Cystic Carcinoma of the Oral Cavity;   Stage I Basal Cell Carcinoma of the Lip;   Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage I Lymphoepithelioma of the Nasopharynx;   Stage I Lymphoepithelioma of the Oropharynx;   Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage I Mucoepidermoid Carcinoma of the Oral Cavity;   Stage I Non-small Cell Lung Cancer;   Stage I Salivary Gland Cancer;   Stage I Squamous Cell Carcinoma of the Hypopharynx;   Stage I Squamous Cell Carcinoma of the Larynx;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Nasopharynx;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage I Verrucous Carcinoma of the Larynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage IA Esophageal Cancer;   Stage IB Esophageal Cancer;   Stage II Adenoid Cystic Carcinoma of the Oral Cavity;   Stage II Basal Cell Carcinoma of the Lip;   Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Lymphoepithelioma of the Oropharynx;   Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage II Mucoepidermoid Carcinoma of the Oral Cavity;   Stage II Non-small Cell Lung Cancer;   Stage II Salivary Gland Cancer;   Stage II Squamous Cell Carcinoma of the Hypopharynx;   Stage II Squamous Cell Carcinoma of the Larynx;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage II Verrucous Carcinoma of the Larynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Esophageal Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Esophageal Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
36 Terminated Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Poorly Differentiated Carcinoma;   Stage IVA Salivary Gland Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
37 Unknown  MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Procedure: blood-oxygen-level-dependent functional magnetic resonance imaging;   Procedure: diffusion tensor imaging;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: functional magnetic resonance imaging;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy treatment planning/simulation
38 Completed Family Quality of Life Among Families With a Member Who is a Cancer Patient
Conditions: Breast Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Lung Cancer;   Prostate Cancer;   Solid Tumor
Interventions: Other: questionnaire administration;   Other: survey administration;   Procedure: quality-of-life assessment
39 Unknown  Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
Condition: Head and Neck Cancer
Intervention: Biological: trastuzumab
40 Active, not recruiting Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Conditions: Head and Neck Cancer;   Mucositis;   Oral Complications of Radiation Therapy;   Pain
Interventions: Drug: doxepin hydrochloride;   Other: placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-52) Show next page of results    Last Page
Indicates status has not been verified in more than two years